

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?
1 in 23 gauge
2. Name the most common side effects a patient may experience when taking Invega Sustenna®.
Increased risk of death in elderly people, injection site reaction, drowsiness, dizziness, feeling restless, tremor, shuffling, uncontrolled movements of eyes, NMS, tardive dyskinesia, changes in blood cell counts
3. What black box warning is associated with this medication?
Risk of death in elderly patients w/ dementia related psychosis
4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?
Day 1: 234 mg Day 8: 150 mg
5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?
117 mg
6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?
Deltoid or ~~gluteal~~ IM
7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?
Day 1: 150mg Day 8: 117 mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

78 mg

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

For patients who haven't taken it before they should establish tolerability

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

Grasp needle sheath using plastic peel pouch, pull w/ straight pull, clean injection site for 15 sec w/ alcohol. Remove rubber tip cap clockwise

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

This medication has serious side effects and the patient should be aware of them before starting this medication.